Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cidara Therapeutics, Inc. - Common Stock (NQ:CDTX)

21.31 -0.79 (-3.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 127,800
Open 22.60
Bid (Size) 20.00 (1)
Ask (Size) 22.60 (10)
Prev. Close 22.10
Today's Range 21.25 - 22.60
52wk Range 10.14 - 28.42
Shares Outstanding 49,506,268
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CDTX Stock Earnings: Cidara Therapeutics Beats EPS, Misses Revenue for Q2 2024
CDTX stock results show that Cidara Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
CDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory

Performance

YTD
-21.9%
-21.9%
1 Month
-20.8%
-20.8%
3 Month
-7.7%
-7.7%
6 Month
-7.7%
-7.7%
1 Year
+82.1%
+82.1%

More News

Read More
CDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
Via TheNewswire.com
Topics Regulatory Compliance
Exposures Legal Regulatory
CDTX Stock Earnings: Cidara Therapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
CDTX INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
From The Rosen Law Firm PA
Via GlobeNewswire
Why Cidara Therapeutics (CDTX) Stock Is Falling
Via Benzinga
Earnings Scheduled For May 8, 2025
Via Benzinga
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
From Phathom Pharmaceuticals
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology
Via Talk Markets
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
CDTX LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
CDTX LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
Via TheNewswire.com
Topics Regulatory Compliance
Exposures Legal Regulatory
CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
From The Rosen Law Firm, P.A.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Why Teradyne Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
CDTX Stock Earnings: Cidara Therapeutics Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Crude Oil Rises Over 1%; Cidara Therapeutics Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities

Frequently Asked Questions

Is Cidara Therapeutics, Inc. - Common Stock publicly traded?
Yes, Cidara Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Cidara Therapeutics, Inc. - Common Stock trade on?
Cidara Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cidara Therapeutics, Inc. - Common Stock?
The ticker symbol for Cidara Therapeutics, Inc. - Common Stock is CDTX on the Nasdaq Stock Market
What is the current price of Cidara Therapeutics, Inc. - Common Stock?
The current price of Cidara Therapeutics, Inc. - Common Stock is 21.31
When was Cidara Therapeutics, Inc. - Common Stock last traded?
The last trade of Cidara Therapeutics, Inc. - Common Stock was at 06/18/25 04:00 PM ET
What is the market capitalization of Cidara Therapeutics, Inc. - Common Stock?
The market capitalization of Cidara Therapeutics, Inc. - Common Stock is 1.05B
How many shares of Cidara Therapeutics, Inc. - Common Stock are outstanding?
Cidara Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.